HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Climb In Consumer Self-Care, Slide In Rx Margin Boost Front-Of-Store Pharmacy Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

OTC drug and supplement marketers could benefit from stronger outreach to independent pharmacists, via product education and patient sales collateral, pharmacists say in a Healthcare Distribution Management Association survey.

You may also be interested in...



Pharmacy Interests Back BTC Models For Third Class

Retailers CVS and Walmart, as well as the National Association of Chain Drug Stores, advocate for a central role for pharmacists in enabling a new class of nonprescription drugs. In comments to FDA, NACDS also supports a switch model that will protect the existing OTC class.

Switch Sponsors Find Key Partners In Payers, Providers and Managed Care

Over-the-counter switch programs that engage health care professionals as partners generate two to three times the consumer awareness as those that do not, said Rohinish Hooda, VP of upper respiratory at McNeil Consumer Healthcare

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

Topics

UsernamePublicRestriction

Register

RS123836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel